Post hoc health-related quality of life analysis according to response among patients with prostate cancer in the PROSELICA and FIRSTANA studies.

The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) or chemotherapy-naïve mCRPC, respectively.